Jardiance empagliflozin regulatory update

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) extended its safety review of Type II diabetes drug Invokana canagliflozin from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) to include similar sodium-glucose cotransporter 2 (SGLT2) inhibitors Jardiance empagliflozin from Eli Lilly and Boehringer and Forxiga dapagliflozin from AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.). In April, the PRAC began reviewing Invokana after an increase in amputations, mostly affecting toes, was observed in the international Phase III CANVAS trial (see BioCentury, April 25). ...